hotspot -WSS

hotspot

author：Wikipedia 2025-09-06 06:16:56 - browse：34

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Readout Newsletter: Bristol, Sangamo, Gilead, and more

focus

WSS

RaDonda Vaught links Vanderbilt hospital issues to patient death

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Bring on the sabbaticals for nurses

Chinese researcher claims birth of first gene

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

RaDonda Vaught links Vanderbilt hospital issues to patient death

knowledge

hotspot

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

explore

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: CAR

United colonoscopy coverage change 'may cost lives,' doctors say

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

23andMe had bad news about my health. I wish a person had delivered it

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Malaria cases in Florida and Texas: Here’s what you need to know

What Kate Middleton's cancer revelation might teach the world

knowledge

Pfizer, Moderna say biotech, pharma drug development is a sprint

How many hemophilia patients actually want gene therapy?

EPA limits use of carcinogenic gas for sterilizing medical devices

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Readout Newsletter: CAR

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

entertainment

knowledge

focus

focus